A Combination Therapy for the Treatment of Constipation-predominant Irritable Bowel Syndrome
Constipation-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is a functional bowel disorder characterised by symptoms including abdominal pain or cramping, bloating, diarrhoea and/or constipation. 10-15% of the world population suffers from IBS. The cause of IBS remains unknown.
IBS may be either diarrhoea-predominant or constipation-predominant or alternating between both.
There is currently no effective treatment or cure for IBS. Therapy may vary from a change in diet to the use of various medications, such as laxatives or drugs that change the motility of the bowel. While such treatments relieve symptoms for some patients, a large proportion of patients continue to suffer.
Ibaconda® is a combination of olsalazine and colchicine which have been identified as providing effective relief to patients with constipation-predominant IBS when used in combination.
Olsalazine is an anti-inflammatory medication currently used to treat ulcerative colitis that produces a laxative effect. Colchicine is a drug that, for many years, has been used to treat gout. It has also demonstrated some efficacy when used to treat the symptoms of constipation.
Both of these drugs when used as single agents are only moderately effective in some patients. Prof. Borody’s experience with olsalazine and colchicine at the Centre for Digestive Diseases suggests that, when used together, these drugs provide more effective relief of constipation than either of the two drugs used alone. On this basis Giaconda believes that this combination will offer an effective treatment alternative for patients with constipation-predominant IBS and is conducting further research in this area.
Please note that Giaconda has no control over the information provided on these sites and is not responsible for the accuracy or otherwise of any information contained on them. If any of the links are no longer working, please notify us.
It has been reported that approximately 30% of IBS sufferers take sick leave for it, with half of these being absent from work at least two weeks per year.